CORDRAN N
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CORDRAN N (CORDRAN N).
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
| Metabolism | Flurandrenolide: primarily hepatic via CYP450 enzymes; Neomycin: minimally absorbed through intact skin, but absorbed if applied to large areas or damaged skin; systemic neomycin is excreted renally unchanged. |
| Excretion | Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine. |
| Half-life | Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application. |
| Protein binding | Corticosteroids: ~90% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Flurandrenolide (active component): Vd ~0.5-1 L/kg. Distributes into extracellular fluid; limited tissue binding. |
| Bioavailability | Topical: Systemic bioavailability low (≤5%) with intact skin; enhanced with occlusion or inflamed skin. No oral formulation available. |
| Onset of Action | Topical: Relief of pruritus within 24-48 hours; anti-inflammatory effect evident by 3-5 days. |
| Duration of Action | Topical: Duration of effect 6-8 hours per application. Clinical improvement sustained with regular use; effects reversible upon discontinuation. |
| Molecular Weight | 436.5 |
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Use lowest potency formulation; limit to smallest amount and shortest duration necessary. Avoid in children <2 years. |
| Geriatric use | Use with caution due to thinner skin; apply sparingly and limit duration to minimize systemic absorption and adverse effects. |
| 1st trimester | Topical corticosteroids like flurandrenolide (Cordran N) are not recommended during the first trimester due to potential risk of fetal abnormalities. Use only if clearly needed and benefit outweighs risk. Limited data suggests increased risk of oral clefts with systemic exposure; topical application minimized systemic absorption but caution advised. |
| 2nd trimester | Use during the second trimester should be cautious, avoiding prolonged use or application to large areas. Topical corticosteroids are generally considered relatively safe with minimal systemic absorption, but high potency or extensive use may pose risks. |
| 3rd trimester | In the third trimester, use only if necessary and for short durations. Prolonged use may lead to potential suppression of fetal adrenal function or low birth weight. Avoid application to large skin areas or occluded sites. |
Clinical note
Comprehensive clinical and safety monograph for CORDRAN N (CORDRAN N).
| Placental transfer | Flurandrenolide is a corticosteroid; placental transfer can occur, but topical use results in low serum concentrations so transfer is limited. Systemic corticosteroids are known to cross the placenta with potential fetal effects; minimal transfer expected with topical application due to low systemic bioavailability. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to flurandrenolide or any component of the formulationUntreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis)Perioral dermatitisRosacea
| Precautions | Prolonged use may cause hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, or local atrophy. Avoid use in large quantities or on occluded areas. Neomycin may cause ototoxicity, nephrotoxicity, or neurotoxicity if significant systemic absorption occurs; avoid use in patients with renal impairment. Monitor for overgrowth of non-susceptible organisms. |
| Food/Dietary | No known food interactions with topical flurandrenolide/neomycin. However, patients with a history of aminoglycoside allergy should be cautious with systemic absorption. No dietary restrictions required. |
Loading safety data…
| Breastfeeding | Topical flurandrenolide is applied externally; systemic absorption is minimal and unlikely to result in clinically significant levels in breast milk. However, avoid application to nipples to prevent infant exposure. Use lowest potency and shortest duration possible. No specific adverse effects reported in breastfed infants, but caution with prolonged or high-dose use. |
| Lactation Rating | L2: Probably Compatible (least likely to cause adverse effects in infants, considered safer, but limited data). |
| Teratogenic Risk | Pregnancy Category C. Topical corticosteroids should be used during pregnancy only if potential benefit justifies potential risk to fetus. Avoid prolonged use or use over large areas, especially in first trimester. Systemic absorption may cause fetal growth restriction, adrenal suppression. No adequate human studies; animal studies show teratogenicity with systemic corticosteroids. |
| Fetal Monitoring | Monitor fetal growth if used for prolonged periods or over large body surface area. Assess maternal adrenal function if signs of hypercortisolism. Evaluate skin for atrophy or infection. |
| Fertility Effects | No known adverse effects on fertility with topical use. Systemic corticosteroids may impair fertility; no data on topical use. |
| Clinical Pearls | CORDRAN N (flurandrenolide with neomycin) combines a potent corticosteroid with a topical aminoglycoside antibiotic. Its use is limited to short-term treatment of steroid-responsive dermatoses complicated by bacterial infection. Do not use for longer than 2 weeks due to risk of neomycin sensitization, systemic absorption, and skin atrophy. Avoid application to large body surface areas, intertriginous areas, or under occlusive dressings without careful monitoring. Potency is comparable to a class II corticosteroid. |
| Patient Advice | Use only on affected areas; do not apply to face, groin, or axillae unless directed by your healthcare provider. · Wash hands before and after application unless treating hands. · Apply a thin layer to the affected skin and rub in gently. · Do not wrap, bandage, or cover the treated area unless instructed. · Avoid prolonged use (more than 2 weeks) to reduce risk of skin thinning and antibiotic resistance. · Notify your doctor if irritation, burning, or signs of allergic reaction develop. · Do not use on open wounds or broken skin. · Keep away from eyes and mucous membranes. · Do not share this medication with others even if they have similar symptoms. |